Gene Editing
Overview
R&D Platforms
Manufacturing
Papers & Presentations
Our Pipeline
Our Pipeline
Ex Vivo
Therapies
In Vivo
Therapies
Our Focus
Genetic Diseases
Cancer
About Us
Company Overview
Scientific Founder
Leadership
Contact Us
Careers
Company Culture
Join Us
News
Press Releases
In the Media
简体中文
中文
Edit Code of Life,
Creating Transformative Solutions for Serious Human Diseases
Press Releases
In the Media
>
News
>
Press Releases
Press Releases
All
2023
2022
2021
2020
2019
2018
Search
13
2020-10
EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage
LEARN MORE
18
2022-11
EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia
LEARN MORE
27
2020-05
EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer
LEARN MORE
29
2020-04
EdiGene to Present Data on its Lead RNA Base Editing Program to Treat Patients with the Most Severe Form of MPS I
LEARN MORE
07
2019-11
EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development of its Leading Gene Editing Therapeutic Program to Treat Patients with β-Thalassemia Major
LEARN MORE
28
2019-10
Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio
LEARN MORE
28
2019-10
Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer
LEARN MORE
18
2019-07
Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs
LEARN MORE
03
2019-04
EdiGene Announced Strategic Collaboration with Genetron
LEARN MORE
13
2019-02
Genome Editing Biotech EdiGene Raises $10 Million in Series pre-B Plus Financing and Strengthens Management Team
LEARN MORE
1
2
3
4
